Patients with obesity were more often treated with β-blockers, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin II receptor blockers, diuretics, statins, and mineralocorticoid receptor antagonists at inclusion. Here, NR3C2 is linked to obesity disorder.